Amgen vs ANI Pharmaceuticals
Amgen vs ANI Pharmaceuticals, compared side by side on 21 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Amgen is on 34/100 and ANI Pharmaceuticals on 49/100.
Where each one leads
Amgen
- agent readiness: 41/100 against 31/100
- domain rating: 80/100 against 56/100
- headcount: 39,919 against 707
- LinkedIn following: 1,697,311 against 31,660
ANI Pharmaceuticals
- our overall score: 49/100 against 34/100
- funding raised: $671M against $40.0M
At a glance
| Measure | Amgen | ANI Pharmaceuticals |
|---|---|---|
| What it is | A global biotechnology company discovering, developing, manufacturing, and delivering innovative human therapeutics. | Diversified biopharmaceutical company focused on rare diseases, generics, and established brands. |
| Category | Biotech, MedTech, HealthTech, Genomics | Biotech, Pharmaceuticals, Rare Disease, Generics |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Software | hardware | services | marketplace | platform |
| Founded | 1980 | 1996 |
| Headquarters | Thousand Oaks, United States | Baudette, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | Amgen | ANI Pharmaceuticals |
|---|---|---|
| Employees | 39,919 | 707 |
| Headcount growthLast 12 months | Not published | +95.8% |
| Total funding | $40.0M | $671M |
| Latest round | IPO | Acquisition |
| LinkedIn followers | 1,697,311 | 31,660 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Amgen | ANI Pharmaceuticals |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 34/100 | 49/100 |
| Traction | 58/100 | 60/100 |
| Team | 70/100 | 10/100 |
| Community | 8/100 | Not published |
| Search visibility | 68/100 | 23/100 |
| Quality | 15/100 | 58/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (41/100) | F (31/100) |
| Domain ratingLink authority, 0-100 | 80/100 | 56/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Amgen | ANI Pharmaceuticals |
|---|---|---|
| Hosting | AWS | Self Managed |
| CDN | CloudFront | Not detected |
| Frameworks | Bootstrap | Jquery, Bootstrap |
| Analytics | Google Tag Manager | Google Analytics 4 |
Amgen vs ANI Pharmaceuticals: common questions
Which is better, Amgen or ANI Pharmaceuticals?
On our 0-100 score ANI Pharmaceuticals rates higher (49/100 against 34/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 21 data points above: read the rows that match what you are buying for.
How do Amgen and ANI Pharmaceuticals compare on the numbers?
Amgen leads on agent readiness (41/100 against 31/100), domain rating (80/100 against 56/100), headcount (39,919 against 707), LinkedIn following (1,697,311 against 31,660). ANI Pharmaceuticals leads on our overall score (49/100 against 34/100), funding raised ($671M against $40.0M).
Read the full Amgen review and pricing or the ANI Pharmaceuticals review and pricing. You can also browse other Amgen alternatives we track.

